Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa — Stella

Home/Epidermolysis Bullosa/

View on ClinicalTrials.gov

Recruiting

Back to Epidermolysis Bullosa trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Stanford University, Redwood City, California

Key details

Phase

Early testing / Safety & dosing

Sponsor

M. Peter Marinkovich

Collaborators

Epidermolysis Bullosa Research Partnership

Enrollment target

~8 participants

Started

August 2025

Primary completion

March 2027

Age range

6 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.